Market Newsdesk

Mechelen, Belgium; 23 December 2020, 18.00 CET – Galapagos NV (Euronext & NASDAQ: GLPG) today announces that Onno van de Stolpe, CEO of Galapagos, has committed to make a personal €10 million donation to African Parks, a non-profit organization that serves at the front lines of wildlife conservation, ecosystem restoration, and community development. The €10 million donation will be in the form of ordinary shares of Galapagos, donated by Mr. van de Stolpe to African Parks and spread over the coming five years. The first €2 million (25,150 ordinary shares held by Mr. van de Stolpe) have been transferred on 22 December 2020.

“I strongly believe that we all have a responsibility to make this world a better place.” said Onno van de Stolpe: “For me, African Parks is a very worthy cause to contribute to in order to make this happen. Saving the African nature reserves for future generations, with their animals, flora and in harmony with the local populations, is providing hope in a world that urgently needs it.”

“We are extremely grateful to Onno in making this very generous commitment to African Parks, where our vision is to make the parks under our management ecologically, socially and financially sustainable,” said Peter Fearnhead, CEO of African Parks. “A gift like this one is just so important for building the longterm financial base necessary to sustain the portfolio of 19 parks spanning 14.5m hectares. And the timing is essential in that protecting nature now is more important than ever, and inextricably linked to the health of our planet and our very own survival.”

About African Parks

African Parks is a non-profit conservation organisation that takes on the complete responsibility for the rehabilitation and long-term management of national parks in partnership with governments and local communities. We currently manage 19 national parks and protected areas in 11 countries covering 14.5 million hectares in: Angola, Benin, Central African Republic, Chad, the Democratic Republic of Congo, Malawi, Mozambique, the Republic of Congo, Rwanda, Zambia and Zimbabwe. For more information visit www.africanparks.org, Twitter, Instagram and Facebook.

About Galapagos

Galapagos NV discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Contacts

Investors:

Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Senior Director Investor Relations
+32 485 19 14 15
[email protected]

Media:

Carmen Vroonen
Global Head of Communications & Public Affairs
+32 473 824 874

Anna Gibbins
Senior Director Therapeutic Areas Communications
+44 7717 801900
[email protected]

Attachment

• Galapagos’ CEO makes donation of €10 million in the form of personal shares

Cincinnati, Ohio, Dec. 23, 2020 (GLOBE NEWSWIRE) — One of the most heavily debated US Constitutional Amendments, the Second Amendment, outlines the right to bear arms, but not everyone reads the copy the same.  The Second Amendment collection from Osborne Mint identifies one side of this debate – those in support of gun freedoms.  The four round collectibles in the series showcase the views of staunch supporters of the Second Amendment’s phrase “the right to bear arms”.  Osborne Mint designs, crafts and strikes all of their collectibles in Cincinnati, Ohio.  These Made In America collectibles are known for their craftsmanship, metal purity and true authenticity.

   
“Who would believe that 27 words, written and ratified over 225 years ago, could still be having such an explosive and divisive impact on our country?  These collectibles are designed, not in support or opposition of either side of the argument, but solely to draw attention to the separation created,” stated Gibson Olpp, Marketing Director for Osborne Mint.

Available by special order, these rounds can be minted in either .999 pure fine silver, copper, brass or nickel silver with the opportunity to personalize the reverse side, or these handcrafted designs can share a common reverse scribing the actual verse of the 2nd Amendment.  The words on the reverse of this version of the rounds were first written in 1791 by James Madison and were included as one of ten amendments forming the Bill of Rights.  Congress ratified all ten amendments in December 1791 and they became law. One lesser-known controversy regarding this amendment revolves around the way it was written. Madison’s wording is a little confusing and leaves the true meaning up for interpretation. Thomas Jefferson even attempted to clarify its meaning by removing two commas.  The first phrase below shows Madison’s version and the second shows Jefferson’s proposed corrections.

1. A well regulated Militia, being necessary to the security of a free State, the right of the people to keep and bear Arms, shall not be infringed. (James Madison version)
2. A well regulated Militia being necessary to the security of a free State, the right of the people to keep and bear Arms shall not be infringed. (Thomas Jefferson version)

However, Jefferson’s efforts were moot once he discovered that the Amendments had already been shared with the States and agreed upon by Congress. To this day Madison’s stroke of the pen makes a considerable difference in the interpretation of the 2nd Amendment. With Thomas Jefferson’s changes, some read this amendment as solely allowing the right to bear arms in the context of a militia. It is Madison’s original text that we selected for these collectibles.

 
Each of these metal rounds features intricately crafted, uber-detailed engraving dies, that when minted deliver exceptional depth in design.  Each blank is struck twice using a higher pressure setting to ensure the design details have been formed.  This depth enhancement lends the obverse side of the rounds to be three dimensional and more complex in design.  Again you can special order these 2nd Amendment collectible rounds in silver, copper, brass or nickel silver and have the option of a high-polish finish or an antiqued look.

Correspondingly the common reverse we’ve created for these rounds holds the identifying marks for the quality of the copper or silver as being .999 Fine, the true weight of the round, 1 AVPD Oz and the brand mark of Osborne Mint representing integrity, quality and authenticity.  The rounds measure 39mm diameter (1.54” – approximately US silver dollar size) and the thickness is 0.12”. These rounds feature reeded edges and are made coin flip.

The obverse of these collectible rounds offers four distinct designs:

Design 1) “We the People”Capitalizing on the recognition of the first three words of the Declaration of Independence, this copper collectible visually ties the Constitution to the 2nd Amendment by slightly modifying and unifying their copy.  The crown of the round illustrates the American bald eagle along with the Great Seal of the United States to symbolize freedom.  The symbolism continues with the outstretched talons of the Eagle grasping alongside its right spur an olive branch representing peace and the other claw clutching a bundle of 13 arrows (referring to the 13 original states), together they symbolize that the United States has “a strong desire for peace, but will always be ready to protect and defend.”

Design 2) EagleThe intricacies of this design are many; the flurry of the bald eagle’s feathers, the wisp of the golden oak leafs and the unfurling of the banner across the span of the eagle’s outstretched wings.  This collectible headlines with The 2nd Amendment and reinforces the 1791 ratification of the Amendment.  Unifying the symbolic features of the collectible are the presence of two revolvers, the American flag and the words “shall not be infringed.”

  
Design 3) SkullThis realistic rendition of a skull is emblematic of the fact that American citizens are willing to die to protect their Second Amendment rights.  The declarative, bold font, adorned by barbed wire, emphasizes the word PROTECT as a means to take a stand in defense of the Second Amendment.  The simplicity of this design emboldens the message.

Design 4) Minute ManInstantly recognizable and immediately associated with the American Revolution and our country’s fight for freedom, the minuteman represents our militia that was ready to fight “in a minute’s notice.”  The root of the design was inspired by the monument “The Lexington Minuteman” created by Henry Hudson Kitson in 1900.  Osborne Mint took the liberty of modernizing the statue by replacing the musket with a semi-automatic AR-15 rifle.

  
These rounds can be purchased individually or as a set as special order directly from the mint.  Special pricing for bulk purchases and individually designed back panels can be received by simply calling the mint at (800) 488-2646. Serving as America’s oldest private mint, Osborne Mint has struck thousands of designs over the years, from the American Legacy Collection honoring the US Mint’s coinage to the Fight For Freedom’s Sake ingots spotlighting various WWII propaganda posters. 

###

About Osborne Mint: www.OsborneMint.com / #OsborneMint

Established in 1835, Osborne Mint is America’s oldest continuously operating private mint. Osborne Mint is part of the Osborne Coinage family, which includes Osborne Coin, TokensDirect and Van Brook of Lexington. The mint, a 60,000 square foot facility in Cincinnati, Ohio, houses the development, engraving and manufacturing of numismatic quality collectible rounds and coins. Products made by Osborne are manufactured to strict standards for metal purity, weight and dimensions. Osborne Mint strikes thousands of collectible rounds annually and circulates them to the public through certified distributors. Now one can purchase collectibles direct from Osborne Mint through their e-commerce portal (Shop-The-Mint.com). Featured collections include: designs by Lisa Parker, Anne Stokes’ Dragons, The Galaxies and Nebulae, The Fight for Freedom’s Sake and The American Legacy Collection. Gold plate, fine silver and copper collections from Osborne Mint are truly pieces of art and are 100% “Made in America.”

Stay in the know, follow our hashtag: #OsborneMint

For more information on Osborne Mint visit our website at www.OsborneMint.com.

Attachments

• Second Amendment designs
• Commone reverse

Gibson Olpp
Mark-ed-ing
5134709428
[email protected]

 

Paris, Amsterdam, December 23, 2020

Press release

Meeting of the Supervisory Board of Unibail-Rodamco-Westfield on December 23, 2020

On December 23, 2020, the Supervisory Board (SB) of Unibail-Rodamco-Westfield SE (URW), upon the recommendation of its Governance and Nomination Committee (GNC), decided to coopt Ms Cécile Cabanis as Member of the SB. She is also appointed as Chairwoman of the Audit Committee (AC). Ms Cabanis brings to the SB significant knowledge of corporate finance and debt management. Her leadership and board experience will strengthen the SB’s collective skills.

The SB also decided to coopt Ms Julie Avrane-Chopard as member of the SB and member of its AC. Her extensive expertise in the tech industry and strategy will reinforce the SB’s ability to supervise URW’s strategy and execution.

These two cooptations will be subject to ratification by the next Shareholders’ Meeting of URW, on May 12, 2021.

For simplification purposes, effective January 1, 2021, the SB also decided to combine the GNC and the Remuneration Committee (RC) to form a Governance, Nomination and Remuneration Committee (GNRC), to be chaired by Mr Roderick Munsters, the current RC Chairman. The SB also agreed on Mr Colin Dyer stepping down from the GNC and RC and joining the AC, effective January 1, 2021.

Mr Léon Bressler, Chairman of the Supervisory Board of URW, said: “I am very glad to welcome Ms Cécile Cabanis and Ms Julie Avrane-Chopard as new members of Unibail-Rodamco-Westfield’s Supervisory Board. Their leadership, board experience and expertise, especially in corporate finance and technology, will significantly strengthen the Supervisory Board and provide valuable insight to its members. I would like to thank Mr Roderick Munsters for his service as Chairman of the Remuneration Committee and agreeing to chair the new combined Governance, Nomination and Remuneration Committee. I also thank Mr Colin Dyer for providing continuity by joining the Audit Committee. With these announcements the Supervisory Board is in working order with two solid and well balanced committees.”

Biography of Ms Cécile Cabanis

Cécile Cabanis is currently Executive Vice-President, Chief Financial Officer, Technology & Data, Cycles & Procurement, member of the Executive Committee and Vice-Chair of the Board of Directors of Danone. Cécile Cabanis began her career in 1995 with L’Oréal in South Africa as Logistics Manager and Financial Controller before moving to France as Internal Auditor. In 2000, she was appointed Deputy Director Mergers & Acquisitions at France Télécom. Cécile Cabanis joined Danone in 2004, and has served in a range of key positions in finance, including Corporate Finance Director, then head of Business Development. In 2010, she was appointed Vice President Finance for the Fresh Dairy Products division. Since 2015, she is Chief Financial Officer and member of the Executive Committee. She is also a member of Board of Directors and Chair of the Audit & Risks Committee – Schneider Electric; Vice President of the Supervisory Board, Chair of the Appointments and Compensation Committee and member of the Audit Committee of Mediawan; and Chair of the Supervisory Board of 2MX Organic. Ms Cabanis graduated from the Agro Paris Grignon engineering school (now AgroParis Tech). Ms Cabanis, born in 1971, is French.

Biography of Ms Julie Avrane-Chopard

Julie Avrane-Chopard is a former Senior Partner with McKinsey & Company in France, focused on High Technology, Advanced Industries and Talent/Future of work. She served major clients across Europe in high technology, aerospace and defense, transportation and mobility. She brings 25 years’ experience in management consulting, with expertise in digital, corporate strategy, growth, organisation, transformation, mergers and culture and change. Projects range from large-scale transformations and turnarounds to growth strategies and Industry 4.0.  Prior to joining McKinsey’s Paris office, Julie Avrane-Chopard worked for two years as a business analyst in McKinsey’s London office from 1995 to 1997 and as a researcher with Bull Honeywell in Boston in 1993 and Cogema (Areva) in 1994. Julie Avrane-Chopard is a graduate of the École nationale supérieure des télécommunications de Paris and of the Collège des ingénieurs. She also holds an MBA from INSEAD. She is a board member of Valeo, representing FSP, and a board member of Group Monnoyeur. Ms Avrane-Chopard, born in 1971, is French.

Biographies of Mr Colin Dyer and Mr Roderick Munsters are available on URW’s website www.urw.com

For further information, please contact:

Investor Relations 

Samuel Warwood
Maarten Otte 
+33 1 76 77 58 02 
[email protected]

Media Relations

Céline van Steenbrugghe
+33 6 71 89 73 08
[email protected]

About Unibail-Rodamco-Westfield

Unibail-Rodamco-Westfield is the premier global developer and operator of Flagship Destinations, with a portfolio valued at €58.3 Bn as at September 30, 2020, of which 86% in retail, 7% in offices, 5% in convention & exhibition venues and 2% in services. Currently, the Group owns and operates 89 shopping centres, including 55 Flagships in the most dynamic cities in Europe and the United States. Its centres welcome 1.2 billion visits per year. Present on two continents and in 12 countries, Unibail-Rodamco-Westfield provides a unique platform for retailers and brand events and offers an exceptional and constantly renewed experience for customers.
With the support of its 3,400 professionals and an unparalleled track-record and know-how, Unibail-Rodamco-Westfield is ideally positioned to generate superior value and develop world-class projects.
Unibail-Rodamco-Westfield distinguishes itself by its Better Places 2030 agenda, that sets its ambition to create better places that respect the highest environmental standards and contribute to better cities.
Unibail-Rodamco-Westfield stapled shares are listed on Euronext Amsterdam and Euronext Paris (Euronext ticker: URW), with a secondary listing in Australia through Chess Depositary Interests. The Group benefits from an BBB+ rating from Standard & Poor’s and from a Baa1 rating from Moody’s.

For more information, please visit www.urw.com
Visit our Media Library at https://mediacentre.urw.com
Follow the Group updates on Twitter @urw_group, Linkedin @Unibail-Rodamco-Westfield and Instagram @urw_group

 

Attachment

• Meeting of the Supervisory Board of Unibail-Rodamco-Westfield on December 23, 2020

Cincinnati, Ohio, Dec. 23, 2020 (GLOBE NEWSWIRE) — Osborne Coinage has manufactured Made in America minted collectibles since 1835 from their private mint in Cincinnati, Ohio.  With thousands of designs and millions of pieces struck, Osborne Coinage is now paying homage to the men and women in blue with a new stock design.

These men and women are collectively known as the “Thin Blue Line” standing between order and lawlessness.  The police motto “To Protect and Serve” emphasizes the very personification and embodiment of this noble profession.  The latest design, “Back The Blue”, honors the sacrifices these officers make on a daily basis and will become part of Osborne’s permanent stock design collection.  Adding this design to the collection means anyone, from individual collectors to police departments can use it on one side of a coin with no additional charge.

The engraving details include a six-point star, a shield of protection and a line representing the thin blue line.  The design itself depicts a compilation of multiple police, sheriff and constable badges to meld into a universal design.  Originally struck in .999 pure copper, this stock design can easily be minted in fine silver, golden brass or other metals.  Whether for an officer, a union, a support group, or an organization, this “Back The Blue” collectible round can commemorate the daunting task of wearing the uniform.

The symbolic design represents law enforcement’s firm resolve and the four pillars of success:

• Reflection of Courage
• Pledge of Brotherhood
• Tribute to the Fallen 
• To Protect and Serve

This round measures 39mm in diameter (1.54” – approximately silver dollar size) with a thickness of 0.12” and can be paired with any stock design in Osborne’s extensive portfolio on the reverse, again, with no additional charge. This piece can also be customized in celebration of a particular group, unit or precinct.  Osborne Coinage can assist with a complete design work or adapt a logo, phrase or image for the back design.  Different interpretations of the reverse side of this round could allow it to be used as a challenge coin, commemorative souvenir or investment vehicle.

“At Osborne Coinage we are proud of our heritage of support for our Cincinnati police department.  Our intertwined pasts make the “Back The Blue” collectible round a natural for us,” according to Jeff Stegman, CEO of Osborne Coinage, “I can see an entire assortment of coins down the road to honor all of our first responders.”  

Cincinnati, Ohio is noted as one of the first cities in the USA to have a uniformed police force, to have a dedicated police paddy-wagon and now the first city to craft the “Back The Blue” collectible round.

During the Civil War, Osborne Coinage retooled their manufacturing facility to create uniform buttons for both the North and the South.  After the conclusion of the war, there was an excess of buttoned uniform jackets from Cincinnati’s Civil War uniform supplier.  These jackets were later repurposed for the Cincinnati police department.  The Cincinnati paddy wagon had its first load a year or so after New York and Boston commissioned their criminal transport.

The “Back The Blue” coin is directed to law enforcement members, families and friends as a simple way to show their support. The silver version, which will be available for sale in February on www.shop-the-mint.com, will contain one full ounce of .999 fine silver, measure 39 mm in diameter and have a reeded edge.

Rounds featuring the “Back the Blue” design on one side and custom designed reverse can be special ordered in copper, nickel silver, fine silver or  golden brass directly from the mint with a phone call (800) 488-2646. The minimum purchase for silver rounds is 100 pieces. The minimum purchase for most other metals is 250 pieces.

###

About Osborne Coinage: www.OsborneCoin.com / #OsborneCoin

Established in 1835, Osborne Coinage is America’s oldest continuously operating private mint. The family of brands includes: Osborne Mint, TokensDirect and Van Brook of Lexington. The mint, a 60,000 square foot facility in Cincinnati, Ohio, houses development, engraving and manufacturing of quality collectible rounds and coins. Products made by Osborne are manufactured to strict standards for metal purity, weight and dimensions. Osborne strikes millions of coins, tokens, medallions and numismatic quality rounds and bars that are sold through distributors, direct to consumer and B2B. One can purchase collectibles direct from Osborne Coin through their brand-new e-commerce portal – www.shop-the-mint.com and stock political coins and tokens at www.tokensdirectstore.com. 

Stay in the know, follow our hashtag: #OsborneCoin, #OsborneMint 

For more information on Osborne Coinage visit: www.OsborneCoin.com.

Attachments

• Back the Blue Sample Photo 1112320
• Waving_Thin_Blue_Line_Flag_1024x1024

Gibson Olpp
Osborne Coinage
5136815424
[email protected]

• Combination Represents One of Allogene’s Three Strategies to Target BCMA for Multiple Myeloma
• Phase 1 Clinical Trial Expected to Begin in the First Quarter of 2021

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to study ALLO-715, Allogene’s investigational BCMA AlloCAR T therapy, in combination with nirogacestat, SpringWorks Therapeutics’ investigational gamma secretase inhibitor (GSI), in patients with relapsed or refractory multiple myeloma. This combination is part of the company’s multi-pronged strategy to develop a treatment for multiple myeloma and will be deployed in the ongoing UNIVERSAL trial. Enrollment in this cohort is expected to begin in the first quarter of 2021.

“We are delighted that the FDA has cleared our IND application for ALLO-715 in combination with nirogacestat,” said Rafael Amado, M.D., Executive Vice President of Research & Development and Chief Medical Officer of Allogene. “We look forward to investigating this combination as part of our comprehensive anti-BCMA strategy aimed at optimizing cell therapy for patients with relapsed/refractory multiple myeloma.”

Gamma secretase is an enzyme that cleaves BCMA from the surface of myeloma cells. In preclinical models, nirogacestat has been shown to prevent the cleavage and shedding of BCMA, leading to an increase in the cell surface density of BCMA and reduced levels of soluble BCMA.¹ Increasing BCMA surface expression with gamma secretase inhibitor may enable deeper and more durable responses to ALLO-715 in patients with multiple myeloma.

Multiple myeloma is the second most common hematological malignancy in the United States, with 32,270 new cases and 12,830 deaths estimated in 2020.²

The Phase 1 combination trial is being advanced pursuant to a clinical trial collaboration agreement that Allogene and SpringWorks entered into in January 2020. Under the terms of the agreement, Allogene is sponsoring and conducting the Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of the combination, and is assuming all development costs associated with the study, other than expenses related to the manufacturing of nirogacestat and certain expenses related to intellectual property rights. Allogene and SpringWorks have formed a joint development committee to oversee the clinical study.

About ALLO-715

ALLO-715, an AlloCAR T therapy targeting B-cell maturation antigen (BCMA), is a potential novel treatment for multiple myeloma and other BCMA-positive malignancies. Multiple myeloma originates in the bone marrow and it is characterized by abnormalities in plasma cells that reproduce uncontrollably in the bone marrow and other disease sites.³ Multiple myeloma is incurable for most patients, as relapses occur despite most treatments available.⁴ Initial results from the Phase 1 UNIVERSAL study of ALLO-715 in relapsed/refractory multiple myeloma were presented at an oral session of the American Society of Hematology (ASH) annual meeting in December 2020. This study also uses ALLO-647, Allogene’s anti-CD52 monoclonal antibody (mAb), as a part of its differentiated lymphodepletion regimen.

ALLO-715 utilizes the TALEN® gene-editing technology pioneered and owned by Cellectis. Allogene has an exclusive license to the Cellectis technology for allogeneic products directed at the BCMA target. Allogene holds the global development and commercial rights for this investigational candidate.

About Nirogacestat

Nirogacestat is an investigational, oral, selective, small molecule gamma secretase inhibitor in Phase 3 clinical development for desmoid tumors, which are rare and often recurrent, debilitating and disfiguring soft-tissue tumors. Gamma secretase cleaves multiple transmembrane protein complexes, including Notch, which is believed to play a role in activating pathways that contribute to desmoid tumor growth.

In addition, gamma secretase has been shown to directly cleave membrane-bound BCMA, resulting in the release of the BCMA extracellular domain, or ECD, from the cell surface. By inhibiting gamma secretase, membrane-bound BCMA can be preserved, increasing target density while reducing levels of soluble BCMA ECD, which may serve as decoy binding molecules for BCMA-directed therapies. Nirogacestat’s ability to enhance the activity of BCMA-directed therapies has been observed in preclinical models of multiple myeloma.

Nirogacestat has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of desmoid tumors (June 2018) and from the European Commission for the treatment of soft tissue sarcoma (September 2019). The FDA also granted Fast Track and Breakthrough Therapy Designations for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis (November 2018 and August 2019).

About Allogene Therapeutics

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability and timing to initiate a clinical trial of ALLO-715 in combination with nirogacestat; ability to manufacture ALLO-715; the ability of ALLO-715 in combination with nirogacestat to enable deeper or more durable responses; and the potential benefits of AlloCAR T™ therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the SEC, including without limitation in its Form 10-Q for the quarter ended September 30, 2020. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:

Christine Cassiano
Chief Communications Officer
(714) 552-0326
[email protected]

<sup>1
Eastman S, Shelton C, Gupta I, Krueger J, Blackwell C,
Bojczuk
. Synergistic activity of
belantamab
mafodotin
(anti-BCMA immuno-conjugate) with PF-03084014 (gamma-secretase inhibitor) in
Bcma
-expressing cancer cell lines. Blood. 2019;134(supplement_1):4401. doi.org/10.1182/blood-2019-123705.

2

https://www.cancer.org/cancer/multiple-myeloma/about/what-is-multiple-myeloma.html


3 Multiple myeloma – Genetics Home Reference – NIH. Retrieved from https://ghr.nlm.nih.gov/condition/multiple-myeloma#

4
Sonneveld
P,
Broijl
A. Treatment of relapsed and refractory multiple myeloma.
Haematologica
. 2016;101(4):396-406</sup>

Las Vegas, NV, Dec. 23, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Hemp, Inc. (OTC PINK: HEMP), a global leader in the industrial hemp industry with bi-coastal processing centers, announced today “a newly approved plan will allow farmers to become independently licensed by the state, opening the door to commercial production and processing of hemp which will benefit both farmers and sellers of CBD hemp flowers.” According to News Americas, Indiana is now one of the twenty-nine states with approved hemp licensing for commercial businesses.

The article also stated Indiana has started accepting hemp cultivation and processing licenses in November for the 2021 growing season. The state is offering one general hemp license and another one for agricultural hemp seed production. Applicants are also required to submit their personal address, GPS coordinates, where the hemp is located and a legal description of the property used for the hemp operation.

Many other states are also currently negotiating commercial hemp licensing plans with the U.S. Department of Agriculture as farmers increasingly seek to grow hemp for manufacturers seeking cannabidiol (CBD), cannabinol (CBN) and cannbigerol (CBG) for oils, lotions, foods and beverages. With more than 25,000 uses for hemp, farming hemp for textiles, insulation, pet bedding and more are increasing at an exponential rate.

(Source/Credit: News Americas Now)

Hemp, Inc. also continues to aggressively ship out its product line to stores, across the country, over the next few weeks. To date, the King of Hemp® product line consists of Bubba Kush hemp; CBD Pre-rolls, Fortified CBD Pre-rolls, CBD and CBG Caviar/Moon Rocks; and Diamonds (which are 96%-98.7% CBD, the only product like this in the marketplace today). Midnight Express-Find Your Freedom pre-roll line, Hemp, Inc.’s second brand, is also launching and will also later include a total of 50 brands.

As of today, some of those brands will include the Daring and Dashing Smith Brothers (the legendary and infamous smugglers from South Florida); the Dockmaster; The Barron of Barges; The Duke of Dope; Carol the Courier; Al the Good Bad Guy; The Golden Dragon Lady; Randy the Racer; Boston Billy; Dopey Don the Genius; and, more.

The smugglers of yesteryear and will each have their own special strains, blends and flavors.

The other King of Hemp® products already in the market are its Diamonds and Crumbles (smaller Diamond pieces) are dabbable CBD products, derived from a golden-hued high CBD, THC-free distillate taken directly from the hemp plant that includes blends of valuable terpenes. Diamonds and Crumbles promise to deliver the strongest, most potent effects of any other product from the line containing between 96% and 98.7% pure CBD.

The Company’s website for its King of Hemp® line (www.kingofhempusa.com) also has CBD oil tinctures available for purchase. The tinctures are available in two flavors, Natural and Peppermint, and contain full-spectrum hemp oil extracted from the flowers and leaves of hemp plants sustainably sourced from Colorado. They are also compliant with the regulations created by the Colorado Department of Agriculture in regards to industrial hemp. The tinctures contain 0.3% or less THC and are compliant with the 2018 Farm Bill.

To learn more, go to the King of Hemp® website, here.

Those interested in King of Hemp® pre-rolls; hemp-derived CBD tinctures; Caviar; Diamonds; should visit www.kingofhempusa.com or email [email protected].

WHAT IS HEMP, INC.?

What is Hemp, Inc.? With a deep-rooted social and environmental mission at its core, Hemp, Inc. seeks to build a business constituency for the American small hemp farmer, the American veteran, and other groups experiencing the ever-increasing disparity between tapering income and soaring expenses. The Company is on a mission to be a powerful engine for social change and economic revival, worldwide, by providing hemp products that are eco-friendly, sustainable and healthy. Hemp, Inc. executives believe there can be tangible benefits reaped from adhering to a corporate social responsibility plan.

FORWARD-LOOKING DISCLAIMER AND DISCLOSURES

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. The Securities and Exchange Commission (SEC) requires issuers to provide “adequate current information” and Hemp, Inc. does… using the SEC’s Alternative Reporting Standard to publicly report its quarterly and yearly financials.  All current information can be found on www.hempinc.com/hemp-financial-disclosures/. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

Contact:

Hemp, Inc.    

855-436-7688

[email protected]

PHILADLEPHIA, Dec. 23, 2020 (GLOBE NEWSWIRE) — Wistar Institute scientists have discovered a new class of compounds that uniquely combine direct antibiotic killing of pan drug-resistant bacterial pathogens with a simultaneous rapid immune response for combatting antimicrobial resistance (AMR). These finding were published today in Nature.

The World Health Organization (WHO) has declared AMR as one of the top 10 global public health threats against humanity. It is estimated that by 2050, antibiotic-resistant infections could claim 10 million lives each year and impose a cumulative $100 trillion burden on the global economy. The list of bacteria that are becoming resistant to treatment with all available antibiotic options is growing and few new drugs are in the pipeline, creating a pressing need for new classes of antibiotics to prevent public health crises. 

“We took a creative, double-pronged strategy to develop new molecules that can kill difficult-to-treat infections while enhancing the natural host immune response,” said Farokh Dotiwala, M.B.B.S., Ph.D., assistant professor in the Vaccine & Immunotherapy Center and lead author of the effort to identify a new generation of antimicrobials named dual-acting immuno-antibiotics (DAIAs). 

Existing antibiotics target essential bacterial functions, including nucleic acid and protein synthesis, building of the cell membrane, and metabolic pathways. However, bacteria can acquire drug resistance by mutating the bacterial target the antibiotic is directed against, inactivating the drugs or pumping them out. 

“We reasoned that harnessing the immune system to simultaneously attack bacteria on two different fronts makes it hard for them to develop resistance,” said Dotiwala.

He and colleagues focused on a metabolic pathway that is essential for most bacteria but absent in humans, making it an ideal target for antibiotic development. This pathway, called methyl-D-erythritol phosphate (MEP) or non-mevalonate pathway, is responsible for biosynthesis of isoprenoids — molecules required for cell survival in most pathogenic bacteria. The lab targeted the IspH enzyme, an essential enzyme in isoprenoid biosynthesis, as a way to block this pathway and kill the microbes. Given the broad presence of IspH in the bacterial world, this approach may target a wide range of bacteria. 

Researchers used computer modeling to screen several million commercially available compounds for their ability to bind with the enzyme, and selected the most potent ones that inhibited IspH function as starting points for drug discovery.

Since previously available IspH inhibitors could not penetrate the bacterial cell wall, Dotiwala collaborated with Wistar’s medicinal chemist Joseph Salvino, Ph.D., professor in The Wistar Institute Cancer Center and a co-senior author on the study, to identify and synthesize novel IspH inhibitor molecules that were able to get inside the bacteria.  

The team demonstrated that the IspH inhibitors stimulated the immune system with more potent bacterial killing activity and specificity than current best-in-class antibiotics when tested in vitro on clinical isolates of antibiotic-resistant bacteria, including a wide range of pathogenic gram negative and gram positive bacteria. In preclinical models of gram negative bacterial infection, the bactericidal effects of the IspH inhibitors outperformed traditional pan antibiotics. All compounds tested were shown to be nontoxic to human cells. 

“Immune activation represents the second line of attack of the DAIA strategy,” said Kumar Singh, Ph.D., Dotiwala lab postdoctoral fellow and first author of the study. 

“We believe this innovative DAIA strategy may represent a potential landmark in the world’s fight against AMR, creating a synergy between the direct killing ability of antibiotics and the natural power of the immune system,” echoed Dotiwala. 

Co-authors: Rishabh Sharma, Poli Adi Narayana Reddy, Prashanthi Vonteddu, Madeline Good, Anjana Sundarrajan, Hyeree Choi, Kar Muthumani, Andrew Kossenkov, Aaron R. Goldman, Hsin-Yao Tang, Joel Cassel, Maureen E. Murphy, Rajasekharan Somasundaram, and Meenhard Herlyn from Wistar; and Maxim Totrov from Molsoft LLC. 

Work supported by: The G. Harold and Leila Y. Mathers Foundation, funds from the Commonwealth Universal Research Enhancement (CURE) Program and the Wistar Science Discovery Fund; The Pew Charitable Trusts supported Farokh Dotiwala with a Wistar Institute recruitment grant; Additional support was provided by the Adelson Medical Research Foundation and the Department of Defense. Support for The Wistar Institute facilities was provided by Cancer Center Support Grant P30 CA010815 and National Institutes of Health instrument grant S10 OD023586. 

Publication information: IspH inhibitors kill Gram-negative bacteria and mobilize immune clearance, Nature (2020). Online publication.

###

The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.

Darien Sutton
The Wistar Institute
215-870-2048
[email protected]